Navigation Links
6 Years Later, 9/11 Health Questions Linger
Date:9/11/2007

at the findings from the Selikoff center -- founded in the 1980s with political backing from labor unions -- are biased in favor of boosting the number of workers thought to be affected by contaminants.

The center's supporters -- including Stellman -- shot back that the Mount Sinai team's efforts were stymied early on by a lack of federal funding and the government's emphasis that worker health screening, not research, be the focus of their efforts at the site.

So, questions on the long-term health effects of those weeks of grueling work at Ground Zero remain unresolved and may never be resolved due to a paucity of data, the experts said.

"What we don't know certainly weighs much more heavily than what we do know," according to Horovitz.

One thing scientists do understand, he said, is that particles under 2.5 micrometers can lodge in the lungs' tiniest channels for years, potentially causing lung disease, atherosclerosis ("hardening of the arteries"), and even cancers.

Many of these illnesses may not show up for decades. "It is definitely far too early to know what's coming down the road for cancer, for example," Stellman said.

She believes it may never be certain whether Ground Zero exposure was carcinogenic. "Because, tragic and horrifying as [9/11] was, the population exposed may never be big enough [statistically] to actually give us a definite answer," Stellman explained.

The psychological consequences for workers are becoming increasingly clear, however. In another New York City health department report, released in August, researchers found that one in every eight responders and workers has come down with post-traumatic stress disorder (PTSD).

Risks for the troubling condition appear to correlate with the length of time workers spent at the Trade Center site, how soon they arrived after the disaster, and their level of training in dealing with traumatic events, the study
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Larynx transplant restores patients voice after 20 years
2. Test tube babies, 25 years later
3. Valium hits 40 years old, anxiety-free
4. Diabetes cases could double in developing countries in next 30 years
5. Normal Blood Pressure Could Add Over 5 Years To Your Life
6. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
7. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
8. Microbicides could serve to materialise women empowerment in the years to come
9. Declining Rates Of Sperm Donors Over The Past 5 Years
10. Diagnosis of Alzheimers years before clinical signs emerge
11. New Test Can Detect Breast Cancer 8 Years Earlier

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...UCW Academy of Health holds open house at Victoria...ocus) November 8, 2009 -- UCW Academy of Health in...Columbia’s health care industry to attend th...25, 2009. , ,UCW Academy of Health, which offers ...and social services, designs its programs to meet ...
(Date:11/8/2009)...New book called "Preventing and Healing AIDS ...raldo shows that AIDS is a result of multiple, rep...ed immune system stressor agents, which can be eit...l, emotional. , Oakland,...; 8, 2009, cell biologists, physicians, chemists a...
(Date:11/8/2009)...PRNewswire-USNewswire/ -- Today, the House of Repr...kemper, Smith, Ellsworth and Lipinski amendment to.... 3962). The amendment maintains the current polic...or benefits packages that include abortion. It cla...fordability credits and those who do not, can with...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
(Date:11/8/2009)...ov. 8 March of Dimes ho...eon to recognize prominent individuals who are cel...ole models for March of Dimes commitment to improv...imes November Prematurity Awareness Month campaign...n the fight for preemies! ,, (Photo: http://w...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...) --,HearAtLast Holdings, Inc. is proud to announc...art Canada (NYSE: WMT ) to open its 16th hearing-...located at 255 Silver Linden,Dr. in Richmond Hill,... its option under a master licensing agreement wit...
...standard being adopted worldwide by, pharmaceutica... confirming digital iden...ms,(Nasdaq: ALDN ), an information security leade... hardware product,to be certified under the recent...
...Diverse Expertise, MIAMI, Dec. 9 Novis Pharmaceu...oducts to healthcare providers, is pleased,to anno...e President of,Human Resources. Ms. Lopez was most...ating from Florida International,University (FIU)....
...eruse of colorectal cancer screening procedures am...n the January 15, 2008 issue of CANCER, a peer-rev... that only 25 percent of Medicare patients receive... States. The American Cancer Society estimates tha...
... believe or disbelieve a statement is a powerful f...t the basis of these states in the brain is not ye...lief and uncertainty activate distinct regions of ... the Annals of Neurology ( http://www.interscience...
...sone improved pre, - and post-stem cell transplan... dexamethasone -, ATLANTA, Dec...M ) reported the presentation of results from an i...nd,dexamethasone (VcTD) to thalidomide and dexamet...
Other Medicine News:Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 3Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 4Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 2Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 3Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 4Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Many Medicare beneficiaries not receiving colorectal cancer screening 2Health News:Belief, disbelief and uncertainty activate distinct brain regions 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)...STOWN, N.J., Nov. 6 Wats...specialty pharmaceutical company, announced today ...cutive officer, will provide an overview and updat...8th Annual Healthcare Conference on Wednesday, Nov...,, This presentation will be webcast live and c...
(Date:11/6/2009)...ESTON, S.C., Nov. 6 T...g in South Carolina and Georgia throughout the wee...elp uninsured and financially-struggling patients ...iption medicines for free or nearly free. With the...nt, the Partnership for Prescription Assistance (P...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 1New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 2New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 3New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 5Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... Italy, April 26 Schering-Plough Corporation,(NYS...ed interim analysis of,an ongoing Phase II study o... protease inhibitor, in 595 treatment-naive patien... were presented at the 43rd Annual,Meeting of the ...ASL). The,ongoing study evaluates boceprevir in 28...
...Large Study Comparing Leading Hepatitis C Therapie...ide Clinical Practice, MILAN, Italy, April 26 Fi...andomized, clinical study comparing the,leading th...day at the 43rd,Annual Meeting of the European Ass...ing important insights that may help guide clinica...
Other Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
...a laser system with one single wavelength of 1064n...us intensities of either 60 W or 100 W, and it is ...ues. This laser is the classical version of Smart1...tals and clinics which would like to have a versat...
SmartChill
...been designed exclusively for vascular treatments,...epil range which ensures fast amortisation of the ...ems, it can be fitted with a polarised light viewi... target to be treated as well as the operators max...
...:YAG) laser is the ideal instrument for safe, repe...s, the majority of surface lesions can be treated,...e, with a minimum of heat damage and in most cases...dverse side effects. Smart 2940 Plus incorporates ...
Medicine Products: